Breast cancer: Should we assess HER2 status by Oncotype DX Â ®?

Nature Reviews Clinical Oncology

Volumn 9, Issue 1, 2012, Pages 12-14

  Ignatiadis, Michail ^a   Sotiriou, Christos ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA;

BREAST CANCER; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SHORT SURVEY; VALIDATION PROCESS;

BIOLOGICAL ASSAY; BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84655169984     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.188     Document Type: Short Survey

References (10)

1. Ignatiadis, M., Desmedt, C., Sotiriou, C., de Azambuja, E. & Piccart, M. HER-2 as a target for breast cancer therapy. Clin. Cancer Res. 15, 1848-1852 (2009).
2. Paik, S. et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J. Natl Cancer Inst. 94, 852-854 (2002). (Pubitemid 34705057)
3. Wolff, A. C. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J.Clin. Oncol. 25, 118-145 (2007). (Pubitemid 350003059)
4. Sauter, G., Lee, J., Bartlett, J. M., Slamon, D. J. & Press, M. F. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 27, 1323-1333 (2009).
5. Dabbs, D. J. et al. High False-Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study. J. Clin. Oncol. 32, 4279-4285 (2011).
6. Baehner, F. L. et al. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J. Clin. Oncol. 28, 4300-4306 (2010).
7. Noske, A. et al. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Res. Treat. 126, 109-117 (2011).
8. Lehmann-Che, J. et al. Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches. Br. J. Cancer 104, 1739-1746 (2011).
9. Sotiriou, C. & Pusztai, L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790-800 (2009).
10. Oncotype DX® Breast Cancer Assay Quantitative single gene scores. Oncotype DX® Breast Cancer Assay http://www.oncotypedx. com/en-US/Breast/ HealthcareProfessional/QuanitativeScores.aspx (2011).